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Background/Purpose: Biomedical research uses many statistical/bioinformatics tools to find genes 
or proteins differentially expressed between patient group of interest. However, biological elements 
are related to one another in a complex network. Understanding those networks is vital to give results 
meaning in a disease context.  
Treatment-naïve early rheumatoid arthritis (RA) patients  have been described to have different 
histological pathotypes (lympho-myeloid, diffuse-myeloid, pauci-immune fibroid), with 
corresponding molecular signatures, associated with response to conventional synthetic Disease-
Modifying Anti-Rheumatic Drugs (csDMARDs) [Lewis et al. 2019, Cell reports]. Purpose of this 
study was to use a novel pathway analysis approach to determine which gene networks are 
specifically activated in patients with different pathotypes or different response to csDMARDs. 
 
Methods: We analysed RNA-Sequencing of 90 patients with early treatment-naïve RA fulfilling the 
2010 ACR/EULAR Criteria recruited into the Pathobiology of Early Arthritis Cohort (PEAC). A 
detailed network of biological interactions was built starting from the KEGG pathway repository and 
enriched with miRNA interactions from miRTarBase and miRecords. Interactions between 
transcription factors (TFs) and miRNAs were added from TransmiR.  
For each category, the most active links between genes, protein, metabolites and miRNA were 
selected based on their RNA-Sequencing expression values. Links redundantly active in two or more 
categories were removed. The resulting subnetworks show interactions that are active in the selected 
category only.  
 
Results: The interactions networks found for the three pathotypes showed a gene level confirmation 
of the above taxonomy.  The lympho-myeloid pathotype network (373 activator links, 96 inhibitor 
links) is characterized by lymphocyte activation with NFKB and mTOR signalling and recruitment 
via chemokines (for example CCL5, CCL2 and CCL19). We found IL3R signalling and cell survival 
networks to be central in the diffuse-myeloid pathotype (20 activator links, 5 inhibitor links), while 
in a pauci-immune fibroid environment (430 activator links, 99 inhibitor links) remodelling of the 
extracellular matrix and vasculature was prominent (Fig. 1).  
On one hand, patients who had a good EULAR response to csDMARDs showed cell survival 
networks with MAP kinase and STAT signalling around BCL2 (Fig. 2). On the other hand, non-
response was linked to T cell genes and lymphocyte attraction via chemokine signalling (Fig.3).  
 
Conclusion: Our novel approach of investigating gene networks leads to a deeper understanding of 
differences in disease pathotypes and response to treatment. Allowing greater insight into underlying 









Figure 1. Pathotypes networks overview showing different number of nodes, edges and topology 
across the three groups.  
Figure 2. Cell survival genes in patients responding to Disease-modifying anti-rheumatic drug 
(DMARD) treatment. 
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